KRAS and non-small cell lung carcinoma: In the phase 1, garsorasib dose-escalation study in KRAS G12C-mutant NSCLC patients (n=62), partial response occurred in 24 patients (ORR, 38.7%) and stable disease in 32 patients (DCR, 90.3%) (37).